However, Wen et al. revealed through their research that immune cell PD-L1, PD1 and CD8 and tumor cell PD-L1 gain independent prognostic values after adjustment of the TNM stage and that an Immunocore (Abington, UK) computed after a thorough evaluation of CD8+ T-cells and PD-L1/PD-1 can help segregate GC patients having the same stage into low-, medium-, or high-risk subcategories, thus helping to decide immunotherapy for treatment [21]. This evidence concerns the gene CD8A and neoplasm.